GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?
作者信息
Santulli Gaetano, Mone Pasquale, Varzideh Fahimeh
机构信息
Department of Medicine (Division of Cardiology), Einstein Institute for Aging Research, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, New York City, NY, USA.
Department of Molecular Pharmacology, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Neuroimmunology and Inflammation (INI), Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York City, NY, USA.
出版信息
Future Cardiol. 2025 Jan;21(1):5-8. doi: 10.1080/14796678.2024.2433381. Epub 2024 Nov 26.
Abstract
摘要
相似文献
1
GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂：新型抗衰老工具？
Future Cardiol. 2025 Jan;21(1):5-8. doi: 10.1080/14796678.2024.2433381. Epub 2024 Nov 26.
2
The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.注射用胰高血糖素样肽-1（GLP-1）受体激动剂与口服二肽基肽酶-4（DPP-4）抑制剂和钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂的安慰剂反应：一项系统评价和荟萃分析。
Br J Clin Pharmacol. 2016 Jul;82(1):301-14. doi: 10.1111/bcp.12925. Epub 2016 Apr 22.
3
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.在台湾，衰弱对 2 型糖尿病患者 GLP-1 受体激动剂与 SGLT2 抑制剂有效性和安全性的影响：一项回顾性、全国性、纵向研究。
Lancet Healthy Longev. 2024 Sep;5(9):100621. doi: 10.1016/j.lanhl.2024.07.004. Epub 2024 Sep 13.
4
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study.根据丹麦 2 型糖尿病和心血管疾病患者虚弱程度启动 SGLT2 抑制剂和 GLP-1 受体激动剂：一项横断面、全国性研究。
Lancet Healthy Longev. 2023 Oct;4(10):e552-e560. doi: 10.1016/S2666-7568(23)00164-2. Epub 2023 Sep 18.
5
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂对心肾结局的影响：23 项心血管结局试验的网络荟萃分析。
Cardiovasc Diabetol. 2022 Mar 16;21(1):42. doi: 10.1186/s12933-022-01474-z.
6
Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.在 2 型糖尿病患者中使用二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂或钠-葡萄糖共转运蛋白-2 抑制剂与骨折风险的关系：基于人群队列研究的网络荟萃分析。
Front Endocrinol (Lausanne). 2024 Oct 11;15:1410883. doi: 10.3389/fendo.2024.1410883. eCollection 2024.
7
Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.根据 2 型糖尿病患者的虚弱情况比较 SGLT-2 抑制剂、GLP-1 受体激动剂和 DPP-4 抑制剂的心血管有效性和安全性。
Diabetes Care. 2023 Nov 1;46(11):2004-2014. doi: 10.2337/dc23-0671.
8
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.GLP-1 受体激动剂- SGLT-2 抑制剂联合治疗与急性心肌梗死后心血管事件：2 型糖尿病患者的观察性研究。
Cardiovasc Diabetol. 2024 Jan 6;23(1):10. doi: 10.1186/s12933-023-02118-6.
9
Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂的疗效及耐受性：一项系统评价和网状Meta分析
Diabetes Obes Metab. 2020 Jul;22(7):1035-1046. doi: 10.1111/dom.14008. Epub 2020 Mar 18.
10
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖共转运蛋白-2 抑制剂及其联合应用对 2 型糖尿病患者内皮糖萼、动脉功能和心肌做功指数的影响：12 个月治疗后的结果。
J Am Heart Assoc. 2020 May 5;9(9):e015716. doi: 10.1161/JAHA.119.015716. Epub 2020 Apr 24.
引用本文的文献
1
Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system.美国退伍军人事务部医疗保健系统中基于种族的循证使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂情况。
Am J Prev Cardiol. 2025 Apr 7;22:100966. doi: 10.1016/j.ajpc.2025.100966. eCollection 2025 Jun.
本文引用的文献
1
The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better.达格列净在不同血流动力学特征的射血分数降低心衰真实世界人群中的作用：越差越好。
Cardiovasc Diabetol. 2024 Nov 22;23(1):423. doi: 10.1186/s12933-024-02515-5.
2
SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂：哪种是最佳抗衰弱药物？
Lancet Healthy Longev. 2024 Sep;5(9):100632. doi: 10.1016/j.lanhl.2024.08.001. Epub 2024 Sep 13.
3
Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes.钠-葡萄糖协同转运蛋白1/2双重抑制剂索格列净用于2型糖尿病心力衰竭的荟萃分析
ESC Heart Fail. 2025 Apr;12(2):968-979. doi: 10.1002/ehf2.15036. Epub 2024 Sep 10.
4
Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population.司美格鲁肽在心脏代谢疾病中的应用：选择目标人群。
J Cardiovasc Dev Dis. 2024 May 7;11(5):145. doi: 10.3390/jcdd11050145.
5
Editorial: Frailty and oxidative stress.社论：衰弱与氧化应激
Front Aging. 2024 Mar 6;4:1345486. doi: 10.3389/fragi.2023.1345486. eCollection 2023.
6
GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes.GLP1 受体激动剂——超越肥胖和糖尿病的作用。
Cells. 2023 Dec 28;13(1):65. doi: 10.3390/cells13010065.
7
Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease.恩格列净抑制钠-葡萄糖协同转运蛋白2对老年体弱糖尿病肾病患者认知和身体功能损害的影响
Pharmacol Res. 2024 Feb;200:107055. doi: 10.1016/j.phrs.2023.107055. Epub 2024 Jan 2.
8
SGLT2 inhibitors: an evidence-based update on cardiovascular implications.钠-葡萄糖协同转运蛋白 2 抑制剂：心血管影响的循证更新。
Expert Opin Investig Drugs. 2023 Jul-Dec;32(9):839-847. doi: 10.1080/13543784.2023.2263354. Epub 2023 Oct 13.
9
Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白 2 抑制剂对 2 型糖尿病患者肌少症的影响：系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2023 Jul 3;14:1203666. doi: 10.3389/fendo.2023.1203666. eCollection 2023.
10
Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.SGLT2 抑制剂在虚弱中的功能和临床重要性：从肾脏到心脏。
Hypertension. 2023 Sep;80(9):1800-1809. doi: 10.1161/HYPERTENSIONAHA.123.20598. Epub 2023 Jul 5.
Zotero 插件